AR118235A1 - Heterociclos pentacíclicos - Google Patents

Heterociclos pentacíclicos

Info

Publication number
AR118235A1
AR118235A1 ARP200100583A ARP200100583A AR118235A1 AR 118235 A1 AR118235 A1 AR 118235A1 AR P200100583 A ARP200100583 A AR P200100583A AR P200100583 A ARP200100583 A AR P200100583A AR 118235 A1 AR118235 A1 AR 118235A1
Authority
AR
Argentina
Prior art keywords
dione
formula
diazepin
pyrimido
cyclopenta
Prior art date
Application number
ARP200100583A
Other languages
English (en)
Inventor
Takaaki Harada
Shinsuke Hirota
Nobuaki Sato
Koji Hagiwara
Nobuhiro Sato
Yoshihisa Kobayashi
Yu Yoshida
Tamaki HOSHIKAWA
Toshihiko Norimine
Yoshiaki Ohashi
Hikaru YOSHIMURA
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of AR118235A1 publication Critical patent/AR118235A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Compuesto caracterizado porque es seleccionado del grupo constituido por (3aS,14aR)-5-metil-3,3a,5,6-tetrahidro-1H-benzofuro[3’,2’:4,5]pirimido[1,2-a]ciclopenta[f][1,4]diazepin-4,13(2H,14aH)-diona: fórmula (1), (+)-7,7,12-trimetil-1,2,3,6,7,10,11,12,13,15b-decahidropirido[4’’,3’’:4’,5’]tieno[2’,3’:4,5]pirimido[1,2-a]pirrolo[2,1-c][1,4]diazepin-5,9-diona: fórmula (2), (3aS,14aR)-10-fluoro-5-metil-3,3a,5,6-tetrahidro-1H-benzofuro[3’,2’:4,5]pirimido[1,2-a]ciclopenta[f][1,4]diazepin-4,13(2H,14aH)-diona: fórmula (3), (3aS,14aR)-5,8,10-trimetil-3,3a,5,6-tetrahidro-1H-ciclopenta[f]pirido[3’’,2’’:4’,5’]furo[3’,2’:4,5]pirimido[1,2-a][1,4]diazepin-4,13(2H,14aH)-diona: fórmula (4), (3aR,14aR)-10-fluoro-5-metil-3,3a,5,6-tetrahidro-1H-benzofuro[3’,2’:4,5]pirimido[1,2-a]ciclopenta[f][1,4]diazepin-4,13(2H,14aH)-diona: fórmula (5), (3aR,14aR)-5-metil-10-(trifluorometil)-3,3a,5,6-tetrahidro-1H-benzofuro[3’,2’:4,5]pirimido[1,2-a]ciclopenta[f][1,4]diazepin-4,13(2H,14aH)-diona: fórmula (6), (3aS,14aR)-10-(2,2-difluoroetil)-5-metil-2,3,3a,5,6,9,10,11,12,14a-decahidro-1H-ciclopenta[f]pirido[4’’,3’’:4’,5’]tieno[2’,3’:4,5]pirimido[1,2-a][1,4]diazepin-4,13-diona: fórmula (7), (3aS,14aR)-10-(2-metoxietil)-5-metil-2,3,3a,5,6,9,10,11,12,14a-decahidro-1H-ciclopenta[f]pirido[4’’,3’’:4’,5’]tieno[2’,3’:4,5]pirimido[1,2-a][1,4]diazepin-4,13-diona: fórmula (8), (3aS,14aR)-10-(difluorometil)-5-metil-3,3a,5,6-tetrahidro-1H-benzofuro[3’,2’:4,5]pirimido[1,2-a]ciclopenta[f][1,4]diazepin-4,13(2H,14aH)-diona: fórmula (9), (2R,15bR)-2-fluoro-7,7,12-trimetil-1,2,3,6,7,10,11,12,13,15b-decahidro-5H,9H-pirido[4’’,3’’:4’,5’]tieno[2’,3’:4,5]pirimido[1,2-a]pirrolo[2,1-c][1,4]diazepin-5,9-diona: fórmula (10), (+)-(3a,14a-cis)-5,10-dimetil-1,3,3a,5,6,9,10,11,12,14a-decahidrofuro[3,4-f]pirido[4’’,3’’:4’,5’]tieno[2’,3’:4,5]pirimido[1,2-a][1,4]diazepin-4,13-diona: fórmula (11), (3aS,14aS)-5-metil-10-(trifluorometil)-2,3,3a,5,6,14a-hexahidro-1H-benzofuro[3’,2’:4,5]pirimido[1,2-a]ciclopenta[f][1,4]diazepin-4,13-diona: fórmula (12), (-)-12-(2-metoxietil)-7,7-dimetil-1,2,3,6,7,10,11,12,13,15b-decahidro-5H,9H-pirido[4’’,3’’:4’,5’]tieno[2’,3’:4,5]pirimido[1,2-a]pirrolo[2,1-c][1,4]diazepin-5,9-diona: fórmula (13), (3aR,14aR)-5,9-dimetil-2,3,3a,5,6,8,9,10,11,14a-decahidro-1H-ciclopenta[f]pirido[3’’,4’’:4’,5’]tieno[3’,2’:4,5]pirimido[1,2-a][1,4]diazepin-4,13-diona: fórmula (14), (3aR,10R,14aR)-10-fluoro-2,5-dimetil-2,3,3a,5,6,9,10,11,12,14a-decahidro-1H-benzo[4’,5’]tieno[2’,3’:4,5]pirimido[1,2-a]pirrolo[3,4-f][1,4]diazepin-4,13-diona: fórmula (15), (3aS,14aS)-10-(2-metoxietil)-5-metil-2,3,3a,5,6,9,10,11,12,14a-decahidro-1H-ciclopenta[f]pirido[4’’,3’’:4’,5’]tieno[2’,3’:4,5]pirimido[1,2-a][1,4]diazepin-4,13-diona: fórmula (16), y (-)-(3a,14a-trans)-2-(2-fluoroetil)-5-metil-2,3,3a,5,6,14a-hexahidro-1H-benzofuro[3’,2’:4,5]pirimido[1,2-a]pirrolo[3,4-f][1,4]diazepin-4,13-diona: fórmula (17), o una sal farmacéuticamente aceptable de la misma.
ARP200100583A 2019-03-05 2020-03-03 Heterociclos pentacíclicos AR118235A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019039351 2019-03-05

Publications (1)

Publication Number Publication Date
AR118235A1 true AR118235A1 (es) 2021-09-22

Family

ID=72336168

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100583A AR118235A1 (es) 2019-03-05 2020-03-03 Heterociclos pentacíclicos

Country Status (21)

Country Link
US (1) US11358972B2 (es)
EP (1) EP3936190A4 (es)
JP (1) JP7504864B2 (es)
KR (1) KR20210135224A (es)
CN (1) CN113453762B (es)
AR (1) AR118235A1 (es)
AU (1) AU2020232044A1 (es)
BR (1) BR112021015975A2 (es)
CA (1) CA3129861A1 (es)
CL (1) CL2021002144A1 (es)
CO (1) CO2021010512A2 (es)
EA (1) EA202191966A1 (es)
IL (1) IL285511B1 (es)
JO (1) JOP20210219A1 (es)
MA (1) MA55221A (es)
MX (1) MX2021009685A (es)
PE (1) PE20211978A1 (es)
SG (1) SG11202108780PA (es)
TW (1) TWI821537B (es)
WO (1) WO2020179780A1 (es)
ZA (1) ZA202105729B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202100531A (zh) 2019-03-05 2021-01-01 日商衛材R&D企管股份有限公司 五環化合物之鹽及其等之結晶

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE258234C (es)
US4187306A (en) 1977-07-26 1980-02-05 Bayer Aktiengesellschaft Benzodiazepine-diones, a process for their production and their use as medicaments
RU2117670C1 (ru) 1988-10-31 1998-08-20 Эйсай Ко., Лтд. Производные триазоло[1,4]диазепина и способы их получения
TW197442B (es) 1990-02-08 1993-01-01 Pfizer
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5736992A (en) * 1994-10-31 1998-04-07 Hewlett-Packard Pressure regulated free-ink ink-jet pen
KR100203456B1 (ko) 1995-06-20 1999-06-15 한승수 디하이드로에보디아민-에이치씨1를 유효성분으로 함유하는 알츠하이머병에 의한 치매 치료제
CL2004000348A1 (es) 1997-04-15 2005-01-14 Cephalon Inc & Kyowa Hakko Kog Compuesto derivado de estaurosporina bis-n-sustituida, util para potenciar la funcion de neuronas colinergicas, estriadas, del prosencefalo basal y sensoriales.
CL2004000352A1 (es) 1998-05-26 2005-05-27 Cephalon Inc & Kyowa Hakko Kog Uso de compuestos derivados de estaurosporina para potenciar la funcion de neuronas colinergicas, estriadas, de prosencefalo basal y sensoriales.
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
DE10246207B4 (de) * 2002-10-04 2008-04-03 Disetronic Licensing Ag Mikrodialysesonde mit spiralförmiger Leitung
AU2003299378A1 (en) 2002-10-11 2004-05-04 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
CN101084220B (zh) 2004-10-20 2010-12-15 弗·哈夫曼-拉罗切有限公司 卤素取代的苯并二氮杂*衍生物
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
GB201100181D0 (en) * 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
EP3144308B1 (en) * 2014-05-16 2020-06-24 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
PL3680243T3 (pl) 2017-09-07 2022-02-14 Eisai R&D Management Co., Ltd. Związek pentacykliczny
TW202100531A (zh) 2019-03-05 2021-01-01 日商衛材R&D企管股份有限公司 五環化合物之鹽及其等之結晶

Also Published As

Publication number Publication date
EP3936190A1 (en) 2022-01-12
PE20211978A1 (es) 2021-10-05
AU2020232044A1 (en) 2021-09-02
ZA202105729B (en) 2022-08-31
CL2021002144A1 (es) 2022-02-04
CN113453762A (zh) 2021-09-28
SG11202108780PA (en) 2021-09-29
JPWO2020179780A1 (es) 2020-09-10
TWI821537B (zh) 2023-11-11
JOP20210219A1 (ar) 2023-01-30
MA55221A (fr) 2022-01-12
KR20210135224A (ko) 2021-11-12
MX2021009685A (es) 2021-09-10
US11358972B2 (en) 2022-06-14
US20200283452A1 (en) 2020-09-10
TW202100528A (zh) 2021-01-01
EA202191966A1 (ru) 2021-12-08
BR112021015975A2 (pt) 2021-10-05
IL285511A (en) 2021-09-30
CA3129861A1 (en) 2020-09-10
CN113453762B (zh) 2024-06-07
WO2020179780A1 (ja) 2020-09-10
CO2021010512A2 (es) 2021-10-29
EP3936190A4 (en) 2022-11-16
IL285511B1 (en) 2024-06-01
JP7504864B2 (ja) 2024-06-24

Similar Documents

Publication Publication Date Title
RU2015131148A (ru) СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1, 2, 4]ТРИАЗОЛО[1, 5c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ А2А АНТАГОНИСТОВ
AR112788A1 (es) Compuesto pentacíclico
JP2016504363A5 (es)
NZ601128A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
JP2013519707A5 (es)
MX2020002711A (es) Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona.
IL186422A0 (en) Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
NZ590688A (en) imidazo[4,5-b]pyridin-2-one derivatives
HK1095818A1 (en) Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine-a2a-receptor antagonists
TN2016000271A1 (en) Heteroaryl substituted nicotinamide compounds.
NZ623922A (en) Novel tricyclic compounds
NZ751509A (en) Combination therapy with 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
IL220174A0 (en) 5-AMINO - {PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE}-2-AND 7-SUBSTITUTED DERIVATIVES AS ADENOSINE A2A RECEPTOR INHIBITORS
CA2434299A1 (en) Tricyclic androgen receptor modulator compounds and methods
AP2528A (en) Methods for the preparation of (3R,3aS,6aR) hexahydro- furo [2,3-b] furan-3-ol
AR118235A1 (es) Heterociclos pentacíclicos
RU2010101279A (ru) 1-цианоциклопропильные производные в качестве ингибиторов катепсина к
HRP20150235T1 (hr) Derivati pirimidina, njihovo dobivanje i njihova farmaceutska upotreba
IL275522B1 (en) Amine derivatives of ARYL–BIPYRIDINE as phosphatidylinositol phosphate kinase inhibitors
DE60202147D1 (de) Imidazo(1,5-a!pyrimido)5,4-d!benz azepinderivate als gaba-a-rezeptormodulatoren
NZ595413A (en) Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
CA2474823A1 (en) Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
TWI800696B (zh) 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
RU2018140732A (ru) Новые замещенные соединения имидазопиридина в качестве ингибиторов индоламин-2,3-диоксигеназы и/или триптофан-2,3-диоксигеназы
EA202092250A1 (ru) Комбинированные продукты для лечения rsv